Breaking News

GC Biopharma Validates Proprietary Technology to Mitigate Thromboembolic Risks

The company’s proprietary assay effectively mitigates heterophilic antibody interference to precisely measure a critical impurity.

Author Image

By: Patrick Lavery

Content Marketing Editor

GC Biopharma has developed and validated a proprietary enzyme-linked immunosorbent assay (ELISA) to lessen an impurity linked to thromboembolic risks. The ELISA effectively mitigates heterophilic antibody interference in order to precisely measure levels of the critical impurity Factor XI (FXI). GC Biopharma characterizes the assay’s validation as a significant step forward in safety monitoring of intravenous immunoglobulin (IVIG). Significance of Thromboembolic Events IVIG therapy may ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters